Salarius pharmaceuticals inc SLRX.US 總覽分析
SLRX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
SLRX 近期報酬表現
-
Salarius pharmaceuticals inc
3.56%
同產業平均
1.47%
S&P500
與 SLRX 同產業的標的表現
- KAPA Kairos pharma ltd價值 -趨勢 2 分波段 2 分籌碼 1 分股利 1 分查看更多
SLRX 公司資訊
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.